Literature DB >> 22068759

Disabling acne fulminans.

Tiago Pina Zanelato1, Gabriela Maria Abreu Gontijo, Célia Antônia Xavier de Moares Alves, Jacqueline Campoi Calvo Lopes Pinto, Paulo Rowilson Cunha.   

Abstract

Acne fulminans is a rare manifestation that may occur during the evolution of acne vulgaris primarily in male adolescents. Use of isotretinoin, testosterone, and exacerbated immune responses in the body are related triggers. Signs, symptoms and laboratory findings such as fever, hepatomegaly, polyarthralgia, leukocytosis, plaquetose, increased inflammatory markers and transaminases, are characteristic. A bone scan can detect osteolytic lesions in multiple skeletal sites. The treatment is performed with prednisolone, isotretinoin and antibiotics if secondary infection is present. This case describes a male patient with a diagnosis of grade III acne, who developed acne fulminans and bilateral sacroiliitis with inability to ambulate, after initiation of therapy with isotretinoin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068759     DOI: 10.1590/s0365-05962011000700001

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  4 in total

Review 1.  Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based review.

Authors:  Belkıs Nihan Coskun; Burcu Yagiz; Yavuz Pehlivan; Ediz Dalkilic
Journal:  Rheumatol Int       Date:  2019-08-27       Impact factor: 2.631

2.  Hepatitis B, interferon, and acne fulminans in a young girl.

Authors:  Sandeep Arora; Ajay Malik; Dharmendra Kumar; Neha Sodhi
Journal:  Indian Dermatol Online J       Date:  2016 Mar-Apr

3.  Sacroiliitis after use of oral isotretinoin--association with acne fulminans or adverse effect?

Authors:  Ariane Silva Bastos Geller; Roberta Ferreira Nazareth Alagia
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

4.  Acne fulminans.

Authors:  Nelson Guimarães Proença
Journal:  An Bras Dermatol       Date:  2017       Impact factor: 1.896

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.